Business Wire

FONDATION-IPSEN

Share
The 15th Colloque Médecine et Recherche of the Fondation IPSEN in the Endocrinology Series: “Stem Cells in Neuroendocrinology”

Stem cells in adults are the source of the body’s regenerative potential. Dividing and differentiating to replace dying or damaged cells. Discovering the specific signals that activate stem cells holds substantial promise for repairing damaged organs. Recently developed techniques for producing large numbers of stem cells in the laboratory are enabling the investigation of basic stem-cell biology and the creation in vitro models of diseases. Cells are being prepared for transplantation into the body and the relationship between healthy and cancer-forming stem cells is being examined. At the Fondation IPSEN’s annual Colloque Médecine et Recherche in the Endocrine Interactions series, an international panel of speakers reviewed how these potent new techniques are being applied to the control of hormone production by the hypothalamus and pituitary gland, the master neuro-endocrine organs that regulate processes ranging from growth, metabolic control and appetite to sleep, stress and aging. Advancing understanding of this system and our ability to repair it will substantially benefit human health and well-being. This meeting, was held in Paris on December 7th , 2015, was organised by Donald Pfaff (The Rockefeller University, New York, USA ) and Yves Christen (Fondation IPSEN, Paris, France ).

Many of the body’s functions are regulated by endocrine hormones, secreted by glands such as the thyroid, pancreas and adrenals. These are controlled by the pituitary gland, located just below the brain, which in turn is governed by the hypothalamus, in the base of the brain, in response to signals it receives from other parts of the brain. This complex neuro-endocrine regulatory system ensures homeostasis by integrating different body functions and their responses to environmental signals. For example, the response to stressful situations involves the central nervous system, the neuro-endocrine and the immune system. Failure either to activate or terminate these responses may result in anxiety, depression and eating disorders (Alon Chen, Max Planck Institute, Munich, Germany ).

Damage to the hypothalamus and pituitary can result from accident, radiation or tumour growth, with profound consequences that include sleep disturbances, weight gain, abnormal stress responses and age-related conditions. Current hormone replacement treatment is costly and has side effects. Stem-cell therapy, whether by transplanting stem cells grown in vitro or activating intrinsic stem cells offers a much more satisfactory alternative (Pfaff; Karine Rizzoti, MRC National Institute for Medical Research, London, UK ).

Many adult tissues contain nests of stem cells, which are undifferentiated and retain the capacity to proliferate. Each cell division creates one offspring with stem-cell properties and the other, known as a progenitor cell, that can differentiate into a variety of cell types. Studying stem and progenitor cells is providing the information needed for using stem cells to repair damaged human tissues (Inna Tabansky, The Rockefeller University, New York, USA ). This includes understanding the molecular pathways that determine the fate of each cell, how tissues maintain and repair themselves, and the role of cell turnover in organ function. Another important aspect is to discover how tissues are organised in three dimensions, so that transplanted cells can be successfully integrated into living tissue (Tabansky; Rizzoti).

Proliferation and differentiation are triggered by chemical signals from within or outside the tissue, few of which have been identified. Recently discovered stem cells in the pituitary seem to be activated mainly in pathological states: in mice that lack a certain type of hormone-producing cell, functional replacement cells were generated by stimulating this stem-cell population (Hugo Vankelekom, University of Leuven, Leuven, Belgium ). A complex of local signals, some secreted by the stem cells themselves, and environmental influences yet to be identified determine whether stem cells remain quiescent or divide. A signaling pathway well-known in developmental biology promotes proliferation in vitro in a subset of stem cells that give rise to hormone-producing cells (Cynthia Andoniadou, King’s College, London, London, UK ). Differentiation of progenitor cells depends on epigenetic mechanisms, such as chromatin remodeling, that activate genes specific to each type of cell. The choice of differentiation pathway determines the fate of the pituitary-cell progenitors, in this case whether they become cells that secrete melanocyte-stimulating hormone or ones producing adrenocorticotropic hormone (Jacques Drouin, Institut de Recherches Cliniques de Montréal, Montréal, Canada ).

In one part of the hypothalamus, cells known as tanycytes have the properties of neural stem cells and progenitors. In response to a high-fat diet and low levels of the hormone leptin, which signals satiety, they differentiate into neurons. Learning more about these signals may contribute to the treatment of diabetes and obesity (Seth Blackshaw, Johns Hopkins University School of Medicine Baltimore, USA ).

Like all things in life, stem cells have their dark side: under certain conditions, they can seed tumour formation. Various animal models are being used to establish what causes this potential and to understanding why and how tumours form in the pituitary. This is essential to safeguard against stem cells used for transplantation developing into tumours (Vankelekom; Andoniadou; Rizzoti).

Stem cells in culture are also offering new opportunities for unravelling the cellular mechanisms of disease an approach being successfully applied to the study of depression (Patricia Zunszain, Institute of Psychiatry, London, UK ). Stem-cells from the human hippocampus, a part of the brain involved in memory formation, differentiate in response to anti-depressant drugs. On the other hand, the birth of new neurons is suppressed by inflammatory molecules, which are an integral part of depression resulting from stress, and the stress hormone cortisol. In time, it should be possible to tailor treatment for individual patients by determining their inflammatory status.

But perhaps the ultimate goal of stem-cell research is to transplant well-defined cells into humans to replace cells that malfunction as a result of genetic mutation, accident or degenerative processes. The recent discovery that skin fibroblasts taken from a patient can be reprogrammed in vitro, so that they revert to stem or progenitor cells, has been a huge step forward. These induced pluripotent stem cells (iPSC) can be produced in large numbers and because they match the patient’s genotype, complications of graft rejection are avoided. Signal molecules and transcription factors are being identified that can reliably direct these cells to differentiate into the required cell types (Tabansky).

One exciting approach is to grow three-dimensional ‘organoids’ in culture for studying the complex of positional signals involved in generating organ structure. They also be used as models for disease and drug screening, as well as providing tissue for transplantation (Hidetaka Suga, Nagoya Univesrity Hospital, Nagoya, Japan ; Rizzoti). Floating three-dimensional aggregates have been created: one has properties of specific areas of the hypothalamus, including hormone release, and another of pituitary cells releasing adrenocorticotropic hormone. When this cultured tissue is transplanted into mice lacking pituitaries, their hormone levels, physical activity and survival are restored (Suga).

Most promising of all, human mid-brain dopamine neurons, which degenerate in Parkinson’s disease, have successfully been generated in vitro. They are functionally integrated when transplanted into animal models of the disease and regulatory approval for testing in human patients is awaited (Lorenz Studer, Memorial Sloan Kettering Cancer Centre, New York, USA ). The methods employed provide a blueprint for generating progenitor cells for the pituitary and hypothalamic neurons that release corticotrophin-releasing hormone and thyroid-stimulating hormone (Studer; Viviane Tabar, Memorial Sloan Kettering Cancer Centre, New York, USA ). Progenitors for myelin-producing oligodendrocytes also are being created, for repairing the diffuse demyelination that results from radiation damage and causes motor and cognitive deficits (Tabar).

About the Fondation Ipsen
Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation Ipsen is to contribute to the development and dissemination of scientific knowledge. The long-standing action of the Fondation Ipsen aims at fostering the interaction between researchers and clinical practitioners, which is indispensable due to the extreme specialization of these professions. The ambition of the Fondation Ipsen is to initiate a reflection about the major scientific issues of the forthcoming years. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche , dedicated to six main themes: Alzheimer's disease, neurosciences, longevity, endocrinology, the vascular system and cancer science. Moreover the Fondation Ipsen has started since 2007 several meetings in partnership with the Salk Institute, the Karolinska Institutet, the Massachusetts General Hospital, the Days of Molecular Medicine Global Foundation as well as with the science journals Nature, Cell and Science. The Fondation Ipsen produced several hundred publications; more than 250 scientists and biomedical researchers have been awarded prizes and research grants.
You can find other information about Fondation Ipsen on our website:
www.fondation-ipsen.org

Contact:

For further information, please contact:
Isabelle de Segonzac, Image Sept
E-mail : isegonzac@image7.fr
Tel. : +33 (0)1 53 70 74 70

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quectel Announces Industry First 5G-Advanced 3GPP R18 Automotive-Grade Cellular Module, Delivering Unmatched Performance and Reliability2.1.2026 18:00:00 CET | Press release

Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the world's first 5G-advanced (5G-A) automotive-grade cellular module, the AR588MA, establishing it as the industry's highest-performing and most reliable wireless communication product for vehicles. Based on MediaTek's latest-generation MT2739 platform, the AR588MA supports 5G-A communication technology and is the world's first to comply with the 3GPP R18 standard protocol. The module also features both NB-NTN and NR-NTN satellite communication capabilities, supports Dual SIM Dual Active (DSDA) technology, offering improved stability and reliability on cellular connections and includes intelligent driving scenario recognition. Designed in compliance with the AEC-Q104 Grade 2 automotive standard, it delivers faster, more stable connectivity and reliable security for in-vehicle communication and benefiting the on-roof applications like smart antenna for automotive with higher temperatu

Interactive Brokers’ Individual and Hedge Fund Clients Outperformed the S&P 500 on Average in 20252.1.2026 16:00:00 CET | Press release

Lower costs, global market access, and efficient execution contributed to stronger client outcomes. Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that its clients outperformed the S&P 500 Index in 2025, reflecting the benefits of cost efficiency, execution quality, and broad access to global markets. In 2025, Interactive Brokers’ individual clients achieved an average return of 19.20%, compared with the 17.9% return of the S&P 500 Index. During the same period, Interactive Brokers’ hedge fund clients achieved an average return of 28.91%, outperforming the index by approximately 11 percentage points. These results demonstrate how Interactive Brokers helps enhance client returns across the investment lifecycle. Global market access enables clients to allocate capital across various regions and asset classes, while lower trading and financing costs, along with efficient execution, help IBKR investors retain more of their returns over time. “Inv

Aeromexico Repeats as Most On-Time Global Airline; Qatar Airways Claims Platinum Award2.1.2026 11:00:00 CET | Press release

Virgin Atlantic wins new award as most improved airline for on-time performance Aeromexico maintained a 90.02% on-time performance to claim the world's most on-time global airline title for the second consecutive year, according to Cirium's 2025 On-Time Performance Review released today. The Mexican carrier becomes only the second airline to achieve consecutive global wins since Cirium launched the program in 2009, operating 188,859 flights across 23 countries while maintaining industry-leading schedule reliability. Aeromexico Holds Global Lead; Regional Champions Crowned Aeromexico secured the global airline title with 90.02% on-time performance, holding off strong competition from Saudia in second place with 86.53% and SAS with 86.09% in third. The margin between first and third place was 3.93 percentage points, reflecting the strong performance of Aeromexico in 2025. Regional winners included: North America: Delta Air Lines won for the fifth consecutive year with 80.90% on-time perf

Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 08:00:00 CET | Press release

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ®BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI® (eculizumab), OBODENCE® (denosumab), and XBRYK® (denosumab)Pre-filled syringe (PFS) presentation to become available in Europe in the second quarter of 2026 Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizuma

Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 15:00:00 CET | Press release

The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye